S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Russia Ignites West's Battle for Energy Independence (Ad)
Why Invest in High-Yield Dividend Stocks?
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Closing prices for crude oil, gold and other commodities
Look at Honeywell for a Steady and Diversified Stock
Big climate bill; Spending green bucks to boost green energy
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Russia Ignites West's Battle for Energy Independence (Ad)
Why Invest in High-Yield Dividend Stocks?
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Closing prices for crude oil, gold and other commodities
Look at Honeywell for a Steady and Diversified Stock
Big climate bill; Spending green bucks to boost green energy
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Russia Ignites West's Battle for Energy Independence (Ad)
Why Invest in High-Yield Dividend Stocks?
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Closing prices for crude oil, gold and other commodities
Look at Honeywell for a Steady and Diversified Stock
Big climate bill; Spending green bucks to boost green energy
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Russia Ignites West's Battle for Energy Independence (Ad)
Why Invest in High-Yield Dividend Stocks?
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Closing prices for crude oil, gold and other commodities
Look at Honeywell for a Steady and Diversified Stock
Big climate bill; Spending green bucks to boost green energy
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)

Satsuma Pharmaceuticals - STSA Stock Forecast, Price & News

$5.79
-0.21 (-3.50%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.67
$5.99
50-Day Range
$2.90
$6.10
52-Week Range
$2.51
$6.52
Volume
56,290 shs
Average Volume
32,268 shs
Market Capitalization
$182.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Satsuma Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
90.0% Upside
$11.00 Price Target
Short Interest
Healthy
1.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.25
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.88) to ($0.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

397th out of 1,112 stocks

Pharmaceutical Preparations Industry

195th out of 544 stocks

STSA stock logo

About Satsuma Pharmaceuticals (NASDAQ:STSA) Stock

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Satsuma Pharmaceuticals Stock Down 3.5 %

STSA traded down $0.21 during midday trading on Thursday, reaching $5.79. 55,020 shares of the company's stock were exchanged, compared to its average volume of 61,809. The firm has a market capitalization of $182.65 million, a price-to-earnings ratio of -3.00 and a beta of 0.71. Satsuma Pharmaceuticals has a one year low of $2.51 and a one year high of $6.52. The business has a 50-day simple moving average of $4.13 and a two-hundred day simple moving average of $4.09.

Satsuma Pharmaceuticals (NASDAQ:STSA - Get Rating) last announced its quarterly earnings results on Tuesday, May 10th. The financial services provider reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.01). As a group, research analysts anticipate that Satsuma Pharmaceuticals will post -1.88 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Mizuho reaffirmed a "buy" rating and issued a $13.00 price target on shares of Satsuma Pharmaceuticals in a research report on Wednesday, June 1st. HC Wainwright reiterated a "buy" rating on shares of Satsuma Pharmaceuticals in a research note on Tuesday, June 21st.

Receive STSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Satsuma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

STSA Stock News Headlines

Satsuma Pharmaceuticals GAAP EPS of -$0.49
STSA Oct 2021 2.500 put
See More Headlines
Receive STSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Satsuma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

STSA Company Calendar

Last Earnings
11/09/2021
Today
8/12/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Regional Banks
Sector
Medical
Current Symbol
NASDAQ:STSA
CUSIP
85931930
Fax
N/A
Employees
21
Year Founded
2016

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+90.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-51,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.29 per share

Miscellaneous

Free Float
21,704,000
Market Cap
$182.91 million
Optionable
Not Optionable
Beta
0.71

Social Links


Key Executives

  • Mr. John A. Kollins MBA (Age 59)
    Pres, CEO & Director
    Comp: $830k
  • Mr. Thomas P. O'Neil (Age 57)
    Chief Financial Officer
    Comp: $550.08k
  • Dr. Detlef F. Albrecht (Age 61)
    Chief Medical Officer
    Comp: $625.97k
  • Mr. Mic Iwashima (Age 44)
    VP & Head of Operations
  • Mr. Robert Schultz (Age 57)
    VP & Head of CMC
  • Dr. Shannon Strom Ph.D. (Age 46)
    VP & Head of Regulatory Affairs
  • Mr. Robert M. Janosky
    Chief Commercial Officer













STSA Stock - Frequently Asked Questions

Should I buy or sell Satsuma Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Satsuma Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STSA shares.
View STSA analyst ratings
or view top-rated stocks.

What is Satsuma Pharmaceuticals' stock price forecast for 2022?

3 analysts have issued 1-year target prices for Satsuma Pharmaceuticals' stock. Their STSA share price forecasts range from $5.00 to $15.00. On average, they predict the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 90.0% from the stock's current price.
View analysts price targets for STSA
or view top-rated stocks among Wall Street analysts.

How have STSA shares performed in 2022?

Satsuma Pharmaceuticals' stock was trading at $4.50 on January 1st, 2022. Since then, STSA stock has increased by 28.7% and is now trading at $5.79.
View the best growth stocks for 2022 here
.

When is Satsuma Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our STSA earnings forecast
.

How were Satsuma Pharmaceuticals' earnings last quarter?

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) issued its earnings results on Tuesday, November, 9th. The financial services provider reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.09.

What other stocks do shareholders of Satsuma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Satsuma Pharmaceuticals investors own include Verrica Pharmaceuticals (VRCA), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Dynavax Technologies (DVAX), Homology Medicines (FIXX), Gilead Sciences (GILD), Novan (NOVN), Pfizer (PFE) and Akebia Therapeutics (AKBA).

When did Satsuma Pharmaceuticals IPO?

(STSA) raised $75 million in an initial public offering on Friday, September 13th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore acted as the underwriters for the IPO.

What is Satsuma Pharmaceuticals' stock symbol?

Satsuma Pharmaceuticals trades on the NASDAQ under the ticker symbol "STSA."

Who are Satsuma Pharmaceuticals' major shareholders?

Satsuma Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Walleye Capital LLC (0.48%), JPMorgan Chase & Co. (0.15%) and UBS Group AG (0.06%). Insiders that own company stock include Commodore Capital Lp, Detlef Albrecht, Group Holdings (Sbs) Advis Tpg, Louis F Centofanti, Rajeev M Shah and Thomas P O'neil.
View institutional ownership trends
.

How do I buy shares of Satsuma Pharmaceuticals?

Shares of STSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Satsuma Pharmaceuticals' stock price today?

One share of STSA stock can currently be purchased for approximately $5.79.

How much money does Satsuma Pharmaceuticals make?

Satsuma Pharmaceuticals (NASDAQ:STSA) has a market capitalization of $182.65 million. The financial services provider earns $-51,170,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis.

When was Satsuma Pharmaceuticals founded?

Satsuma Pharmaceuticals was founded in 2016.

How can I contact Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals' mailing address is 400 OYSTER POINT BOULEVARD SUITE 221, SOUTH SAN FRANCISCO CA, 64080. The official website for the company is www.satsumarx.com. The financial services provider can be reached via phone at 650-410-3200 or via email at cdavis@lifesciadvisors.com.

This page (NASDAQ:STSA) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.